AstraZeneca, Merck's star PARP inhibitor Lynparza expands reach in ovarian cancer with new US approval

Weeks after GSK widened the market for PARP inhibitor Zejula in patients with ovarian cancer, rival AstraZeneca’s market-leading Lynparza has also secured expanded use in women with the disease.